Page 1

CellaVision Interim report Q1 January - March 2021 Strong profitability and positive development in Europe Organic sales growth : Q1 , 2021 : 7 % ( 1 ) EBITDA margin : Q1 , 2021 : 34 % ( 31 ) 1 January - 31 March 2021 • Net sales were flat versus last year , SEK 134.0 million ( 134.4 ) . • Sales increased organically by 7 % ( +1 ) , currency effect -7 % Jan - Mar ( MSEK ) Net sales 2021 Jan - Mar 2020 Full year • EBITDA amounted to SEK 46.2 million ( 41.2 ) . 2020 134.0 134.4 471.4 • EBITDA margin amounted to 34 % ( 31 ) . Gross profit 93.0 92.3 313.0 EBITDA 46.2 41.2 142.9 EBITDA margin , % 34 31 30 • Profit before tax amounted to SEK 35.6 million ( 25.5 ) . • Earnings per share before and after dilution were SEK 1.19 ( 0.85 ) . • Cash flow from operating activities amounted to SEK 26.2 million ( 15.4 ) . Profit / loss before tax 35.6 25.5 112.2 Total cash flow 8.8 -5.2 0.9 Equity ratio , % 65 57 64 Significant events after the period close " Despite the global pandemic the company has increased its strong profit- ability and generated a strong operating cashflow while not slowing down on R & D investments to keep strengthening the innovation pipeline . " Simon Østergaard , President and CEO • CellaVision acquired the exclusive rights to a patent portfolio containing a new microscopy technology , Fourier Ptychographic Microscopy , from Clearbridge BioPhotonics . The acquisition gives CellaVision access to and control over an interesting future technology . The acquisition price amounted to a cash purchase price of SEK 28.7 million . CELLAVISION